BioNTech is a global immunotherapy company developing novel medicines against cancer, infectious diseases, and other serious conditions through a diversified platform of mRNA therapies, targeted antibodies, cell therapies, and combination approaches. The company generates revenue primarily from its COVID-19 vaccine (Comirnaty) developed with Pfizer and is advancing a pipeline of oncology programs including personalized neoantigen therapies, bispecific antibodies, and antibody-drug conjugates, as well as infectious disease vaccines through strategic partnerships with major pharmaceutical companies. BioNTech operates a fully integrated business model combining discovery, manufacturing, clinical development, and commercial capabilities, with its own GMP-certified production facilities across Europe and international sites enabling both near-term product launches and long-term innovation in immunotherapies.